Putnam Investments’s Neurogene NGNE Stock Holding History

Putnam Investments’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,758	Closed	-$799K	–	1517
2015 Q2	$799K	Hold	5,758	–	–	﹤0.01%	1268
2015 Q1	$988K	Hold	5,758	–	–	﹤0.01%	1200
2014 Q4	$864K	Hold	5,758	–	–	﹤0.01%	1205
2014 Q3	$767K	Hold	5,758	–	–	﹤0.01%	1265
2014 Q2	$1.08M	Hold	5,758	–	–	﹤0.01%	1176
2014 Q1	$1.47M	Buy	+5,758	New	+$1.48M	﹤0.01%	1117

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments's NGNE Position: Q3 2015 in Review

Putnam Investments sold out of Neurogene (NGNE) in Q3 2015, closing a stake of 5,758 shares — an estimated $799K sold.

Putnam Investments first reported a position in NGNE in Q1 2014 and held it in 6 quarters. The position peaked at $1.47M in Q1 2014. 33 funds tracked by Wall St. Rank hold NGNE as of Q3 2015.

Putnam Investments reported no remaining Neurogene position as of Q3 2015 after selling out during the quarter.
Putnam Investments sold 5,758 Neurogene shares in Q3 2015, an estimated $799K.
Putnam Investments first reported a position in Neurogene in Q1 2014 and held it in 6 quarters.
Putnam Investments's Neurogene position peaked at $1.47M in Q1 2014.
33 funds tracked by Wall St. Rank held Neurogene as of Q3 2015.

Based on Putnam Investments's 13F filing for Q3 2015, filed 16 Nov 2015.